搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按相关度排序
按时间排序
GlobalData on MSN
7 天
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
ThePrint on MSN
5 天
Why Indian patients groups are opposing patent requests for blockbuster HIV drug lenacapavir
Granting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...
9 天
Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against ...
newsbytesapp.com
5 天
Meet Lenacapavir: The drug that could end HIV epidemic
Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School ...
10 天
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In ...
Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...
10 天
Gilead’s twice-yearly lenacapavir outperforms Truvada in men
If approved, lenacapavir would be the first and only twice-yearly HIV prevention choice for people who need or want PrEP.
5 天
US-based pharma giant Gilead Sciences wants HIV drug Lenacapavir patented
On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's ...
Yahoo Finance
7 天
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...
infectiousdiseaseadvisor.com
4 天
Twice-Yearly Injectable Lenacapavir Bests Daily PrEP Tablet for HIV Prevention
Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.
mashviral
10 天
Gilead’s Lenacapavir Halts HIV by 96%: Paves Path for FDA Approval
Gilead Sciences disclosed exceptional results from their lenacapavir injectable HIV prevention drug’s Phase 3 trial. The ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈